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Abstract: Probiotic bacteria have beneficial effects to the development and maintenance of a healthy
microflora that subsequently has health benefits to humans. Some of the health benefits attributed to
probiotics have been noted to be via their immune modulatory properties suppressing inflammatory
conditions. Hence, probiotics have become prominent in recent years of investigation with regard
to their health benefits. As such, in the current study, we determined the effects of Streptococcus
thermophilus to agonist MBP83–99 peptide immunized mouse spleen cells. It was noted that Streptococcus
thermophilus induced a significant increase in the expression of anti-inflammatory IL-4, IL-5, IL-10
cytokines, and decreased the secretion of pro-inflammatory IL-1β and IFN-γ. Regular consumption of
Streptococcus thermophilus may therefore be beneficial in the management and treatment of autoimmune
diseases such as multiple sclerosis.
Keywords: probiotics; Streptococcus thermophilus; ST285; MBP83–99 peptide; mannan; immune
modulation; multiple sclerosis; agonist peptide
1. Introduction
There is an increasing trend in immune-mediated disorders across the world that is believed to
be in part, a result of intestinal dysbiosis. The imbalance in the intestinal ecosystem can lead to a
dysfunctional immune system that consequently causes immune disorders including autoimmune
diseases (multiple sclerosis, MS) and other inflammatory disorders [1,2]. Probiotics have long been
implicated for the overall improvement of health and the management of a number of health conditions
including infection, constipation, allergies, and autoimmune diseases, and are either consumed in the
form of different fermented foods and dairy products or taken as capsules. In either case, there is
strong evidence that suggests that the ingestion of probiotics can alter intestinal dysbiosis and relieve
dysfunctionality complications, with subsequent improvements to health [3].
Probiotic bacteria have been evolved inside the human intestinal tract (GIT), and through this
co-evolution, the gut and its microbiome have developed a symbiotic relationship that is of mutual
benefit. While the GIT microflora relies on the gut’s warm habitat and food content, in return, it not
only provides numerous unique bioactive components such as vitamins B and K, minerals, short chain
fatty acids (SCF), and miosins to the host, but it also assists in modulating the immune system [3].
In fact, probiotics are able to modulate monocytes, macrophages, B cells, T helper (h)1, Th2, Th17,
regulatory T cells (Treg), natural killer (NK) cells, and dendritic cells (DC) [3–6].
Chronic inflammation is the pathophysiological condition involved in neuro-degenerative
disorders including MS, Parkinson’s disease, and Alzheimer’s disease [7,8]. There is cross-talk
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between the gut microbiota and the central nervous system (CNS) [8–10], known as the gut–brain
axis. An insufficient or imbalanced GIT microflora can also lead to dysfunctions in the gut–brain axis
and the pathogenesis of a number of diseases inside the GIT (such as inflammatory bowel disease,
IBD) and outside the GIT (such as the CNS). Experimental autoimmune encephalomyelitis (EAE)
is an animal model of human MS that has been used to study the effects of probiotic bacteria on
CNS [11,12]. One of the safe and appropriate ways to modulate T cells in MS is to orally administer
specific autoantigens [13,14]. Administration of Bifidobacteria or Lactobacteria probiotic strains to mice
has been shown to increase Treg cells and tumor growth factor (TGF)-β levels and reduce the severity
of EAE clinical symptoms, in parallel with improvement in the regeneration of myelin in the spinal
cord compared to the control [15,16]. Administration of both Bifidobacteria and Lactobacteria strains
induce an additional significant delay in the onset of EAE and related clinical symptoms, together with
a substantial reduction of mononuclear infiltration into the CNS, and increased level of Treg cells of the
CD4+CD25+Foxp3+ phenotype in mouse spleen and lymph nodes.
In SJL/J mice, immunization with the MBP83–99 peptide mixed with mycobacterium stimulates
autoimmune CD4+ T cells in mice, and induces EAE [7,17]. Major histocompatibility complex (MHC)
class II H-2s haplotype in the SJL/J mouse strain resembles many clinical, histopathological, and
immunological characteristics of human MS, thus the SJL/J mouse is regularly used for immunization
studies. Different peptides are immunogenic in different mouse strains however, in the SJL/J mouse
strain, the peptide MBP81–100 binds to MHC class II H-2s with high affinity with the minimum
epitope being MBP83–99 [7,17]. As such, the MBP83–99 epitope has been used as an agonist peptide
to immunize mice for the activation of CD4+ T cells [7,17]. We have shown that injection of the
MBP83-99 peptide conjugated to the carrier mannan or mixed in complete Freund’s adjuvant induces
Th1 pro-inflammatory interferon-gamma (IFN γ-g) secreting CD4+ T cells [18–25]. Studies have shown
that there is a cross-reactivity between the MBP self-peptide and some microbial peptides (i.e., UL15,
PMM) for Hy.1B11 T cell receptor (TCR), which has been isolated from a patient with MS. It has been
highlighted that there are chemical interactions underlying the recognition mechanisms between TCR
and the peptides presented by MHC proteins, as a critical constituent in adaptive immune responses
to foreign antigens [26].
The Streptococcus genus constitutes over 100 species, amongst which S. thermophilus (ST) are
non-pathogenic and food related bacteria that represent outstanding technological features in the food
industry [27]. ST are commonly used as secondary starter cultures in dairy products to transform
lactose into lactic acid and to acidify the pH of milk [27,28], contributing to both the fermentation and
flavoring of dairy products [29]. Most probiotics belong to lactic acid bacteria (LAB); Gram-positive
lactic acid producing bacteria that include lactobacilli, bifidobacterial, and enterococci [3]. As such, live
LABs are not only used in foods for their health benefits, but exopolysaccharide-producing strains of ST
such as ST1342, ST1275, and ST285 are generally used due to their beneficial properties (i.e., relieving
lactose intolerance and suppressing acute conditions such as acute ulcerative colitis) [29]. Additionally,
experimental studies designed to investigate the effect of VSL3 (Streptococcus, Bifidobacterium, and
Lactobacillus species) on the peripheral immune system and the GIT microbiota in MS patients and
healthy subjects showed improved abundance of many taxa with enriched taxa mainly consisting of
Lactobacillus, Streptococcus, and Bifidobacterium. VSL3 also induced peripheral anti-inflammatory
immune responses [30].
We recently showed that ST bacteria have anti-inflammatory properties [29]. U937 pro-monocytic
cell line co-cultured with three ST bacteria (ST1342, ST1275 and ST285) induced an anti-inflammatory
profile [29]. ST285 was further shown to have immune modulating effects via gene arrays to human
peripheral blood mononuclear cells (PBMC) [31] and monocyte cells isolated from PBMC [32]. Herein,
we immunized SJL/J mice with agonist MBP83–99 peptide conjugated to mannan three times, isolated
spleen cells, and after re-stimulation of spleen cells with the MBP83–99 peptide, IFN-γ was secreted
by spleen cells. Re-stimulation of spleen cells with the MBP83–99 peptide in the presence of ST285
probiotics was able to downregulate IFN-γ responses and stimulate the Th2, IL-4, IL-5, and IL-10
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cytokine profile. These studies show that probiotics are able to modulate and alter the immune profile
of MBP83–99 specific cells to anti-inflammatory, which warrant in vivo EAE mouse experiments and
hold promise as a therapeutic alternative approach to MS in human clinical trials.
2. Materials and Methods
2.1. Bacterial Strains
Pure bacterial cultures of S. thermophilus 285 (ST285) were obtained from the Victoria University
culture collection (Werribee, Vic, Australia). Stock cultures were stored in cryobeads at −80 ◦C. Prior to
each experiment, the cultures were propagated in M17 broth (Oxoid, Denmark) with 20 g/L lactose
and incubated at 37 ◦C under aerobic conditions. Bacteria were also cultured on M17 agar (1.5% w/v
agar) with 20 g/L lactose (Oxoid, Denmark) to assess the characteristics, morphology, purity, and
Gram-positive confirmation [1].
2.2. Preparation of Live Bacterial Suspensions
Media were prepared and autoclaved at 121 ◦C for 15 min prior to the experiments. Bacterial
cultures were grown three times in M17 broth with 20 g/L lactose at 37 ◦C aerobically for 18 h with a 1%
inoculum transfer rate [33]. Cultures grow optimally at 37–42 ◦C for 24 h [29]. The growth period of
cultures were consistent at 18 h (at the end of the exponential growth phase) and before the stationary
growth phase to prevent cell lysis.
2.3. Enumeration of Bacterial Cells
For the actual experiment, bacteria were grown in broth media to the stationary phase at 37 ◦C
aerobically, pelleted by centrifugation (6000× g) for 15 min at 4 ◦C, transferred, and resuspended in
Dulbecco’s phosphate-buffered saline, pH 7.4 (Invitrogen, Pty Ltd. Australia). The bacterial density in
suspension was adjusted to 108 colony forming units (cfu)/mL for final concentration by determining the
optical density at 600 nm, followed by two washes with Dulbecco’s phosphate-buffered saline. These
samples constituted the live-cell suspensions and were resuspended in the Roswell Park Memorial
Institute (RPMI) 1640 culture media prior to co-culturing with spleen cells [1].
2.4. Mouse Experimental Procedures
2.4.1. Mice, Conjugates, and Immunization Schedule
Female SJL/J mice, aged 6–9 weeks, used in all experiments were purchased from the Animal
Resources Center (ARC, Perth, Australia), and accommodated at the animal house (Victoria University,
Werribee campus, Melbourne, Australia). All mice were ensured free access to water and food, and
were housed in a temperature controlled room with a 12 h day 12 h night cycle. All immunizations
were conducted according to the guidelines of the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes and the study was approved by the Victoria University Animal Ethics
Committee (AEC15/013) of Victoria University, Melbourne, Australia.
The MBP83–99 agonist peptide of over 99% purity with (KG)5 at the C-terminus was conjugated to
mannan via a method previously described [34–38]. Briefly, 14 mg of mannan (Sigma, VIC Australia)
was oxidized in sodium carbonate buffer and 0.1 M sodium periodate at 4 ◦C after which ethylene glycol
was added and incubated for 30 min at 4 ◦C. Oxidized mannan comprising aldehyde groups was passed
through a PD-10 column (Sigma, VIC Australia) pre-equilibrated in carbonate-bicarbonate buffer pH
9.0 and 2 mL of oxidized mannan was collected and 1 mg of MBP83–99-(KG)5 peptide was added and
allowed to react overnight at room temperature in the dark. The resultant MBP83–99-(KG)5-mannan
conjugate was used to immunize the mice.
The MBP83–99 mannan peptide conjugate (50 µg/mouse) was injected in the SJL/J mice
subcutaneously into the base of the tail, three times, every two weeks [17]. This conjugate has
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been shown to induce T cell proliferation and IFN-γ cytokine secretion to the agonist MBP83–99 peptide
in SJL/J mice [17,19,23,24]. Ten to fourteen days after the three injections, spleen cells were isolated, red
blood cells were lysed using 0.73% NH4Cl, and counted.
2.4.2. Isolation of Spleen Cells and In Vitro Stimulation with ST285
Spleen cells were resuspended in RPMI 1640 media supplemented with 10% heat-inactivated
fetal bovine serum (Invitrogen, Pty Ltd. Australia), 1% antibiotic-antimycotic solution, and 2 mM
L-glutamine in T75 cm2 cell culture flasks. Mouse spleen cells (1 × 107) in RPMI media only was used
as the negative control, 5 µg/mL recall agonist MBP83–99 peptide was used as the recall control, or
1 × 108 ST285 bacteria were added together with the MBP83–99 peptide, and cultured at 37 ◦C, 5%
CO2 for 24 h [29]. We previously showed that 24 h co-culture was adequate for the stimulation of the
monocyte/macrophage cell line, human peripheral blood mononuclear cells, and human monocytes
isolated from peripheral blood mononuclear cells [29,32]. At the end of the culture period, cells were
transferred into falcon tubes, and centrifuged for 5 min at 1200 rpm to pellet the cells. All cell-free
supernatants were collected and frozen at −20 ◦C until cytokine analysis.
2.5. Cytokine Production Analysis
Cytokine secretion of the spleen cell culture supernatants was analyzed by commercially available
capture and detection antibodies in a Bioplex multiplex bead assay for a panel of nine mouse cytokines
and chemokines using a 9-plex kit (BioRad, Melbourne Australia) to measure Interleukin (IL)-1β,
IL-2, IL-4, IL-5, IL-6, IL-10, GM-CSF, TNF-α, and IFN-γ. Cell-free supernatants were collected and
the assay procedures were performed according to the manufacturer’s instructions. Briefly, a flat
bottom 96-well plate was coated with 1× coupled beads and washed twice, followed by adding the
standard serial dilutions, blanks, and samples to assigned wells. Post incubation at shaking at room
temperature, plates were washed twice, adequate 1× detection antibody was added, and incubated at
room temperature. Plates were washed three times and 1× Streptavidin Phycoerythrin (SA-PE) stop
solution was added to each well, followed by incubating at room temperature and washing. Data
collection was repeated twice, data were expressed as the mean cytokine response minus background
(pg/mL) of each treatment from three replicate wells, plus or minus the standard error of the mean.
2.6. Statistical Analysis
Significant differences between all treatment groups were tested by analysis of variance (ANOVA)
using the Statistical Package for the Social Sciences for Windows 25.0 (SPSS; IBM Corp), followed by a
comparison between treatments performed by Tukey’s honest significance test/degree and Fisher’s
least significant difference method, with a level of significance defined as p < 0.05.
3. Results
3.1. ST285 Reduces Pro-Inflammatory TNF-α and IFN-γ Production by MBP83–99 Primed Mouse Splenocytes
Interferon gamma (IFN-γ) is a pro-inflammatory Th1 cytokine involved in macrophage activation
and cellular immunity. IFN-γ promotes Th1 cells and inhibits Th2 anti-inflammatory cells. In MS,
IFN-γ is induced following CD4+ T cell activation by agonist peptide MBP83–99. SJL/J mice immunized
with MBP83–99–mannan conjugates induced IFN-γ responses by spleen cells, following overnight
MBP83–99 peptide re-stimulation (Figure 1A, p < 0.01). Spleen cells re-stimulated with the agonist
MBP83–99 peptide in the presence of ST285 reduced IFN-γ cytokine secretion (Figure 1A, p < 0.05).
TNF-α, a Th1 cytokine, was not secreted by spleen cells from immunized mice wither by re-stimulation
of the MBP83-99 peptide or MBP83-99 peptide plus ST285 (Figure 1B).
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Figure 1. S. thermophilus 285 reduces pro-inflammatory cytokine production by mouse splenocytes.
Spleen cells isolated from immunized mice (n = 3) were stimulated with S. thermophilus (ST) ST285
and recall agonist MBP83–99 peptide for 24 h and secretion of (A) IFN-γ and (B) TNF-α were measured.
Recall MBP83–99 peptide was used as an internal positive control, and media refers to spleen cells from
immunized mice (n = 3) without any additional recall peptide, or ST285 probiotic bacteria plus the
MBP83–99 peptide. Means of two different readings of three replicate experiments were measured and
analyzed. The means of readings for n = 3 mice were calculated and presented as plus or minus (±) the
standard error of the mean. Symbols represent the p value for the Tukey test (one way ANOVA) where
* p < 0.05 and ** p < 0.01.
3.2. ST285 Decreases Secretion of IL-1β, IL-2, and IL-6 by Mouse Spleen Cells
Secretion of IL-1β was slightly, but significantly reduced in immunized mouse spleen cells
re-stimulated with the MBP83–99 peptide and ST285 compared to no re-stimulation, or the MBP83–99
peptide re-stimulation without ST285 (p < 0.05) (Figure 2A). IL-2 production was significantly increased
in immunized spleen cells re-stimulated with the MBP83–99 peptide (p < 0.01), which was weakly but
significantly decreased as a result of the co-stimulation of mouse spleen cells with the MBP83–99 peptide
plus ST285 (p < 0.05) (Figure 2B). The production of IL-6 was profoundly increased by immunized
mouse spleen cells upon co-culture of ST285 and the recall MBP83–99 peptide compared to the control
media or MBP83–99 recall peptide (p < 0.001) (Figure 2C); spleen cells recalled with the MBP83–99 peptide
alone also increased IL-6 secretion.
3.3. ST285 Induces Anti-Inflammatory Cytokine Profile by Mouse Splenocytes
Mice immunized with the MBP83–99 agonist peptide did not induce IL-4, IL-5, and IL-10
anti-inflammatory cytokines in the control (media alone) and recall agonist peptide MBP83–99 (Figure 3).
However, the Th2 anti-inflammatory cytokine IL-4 was significantly (p < 0.001) increased by immunized
mouse spleen cells when the MBP83–99 recall peptide was co-cultured with ST285 probiotic bacteria
(Figure 3A). IL-5 was also increased by immunized spleen cells following co-culture with ST285 and
the recall agonist MBP83–99 peptide (Figure 3B) (p < 0.01). The anti-inflammatory IL-10 cytokine
was also significantly increased by immunized mouse spleen cells when co-cultured with ST285 and
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agonist recall MBP83–99 peptide compared to the MBP83–99 peptide alone or media control (p < 0.001)
(Figure 3C).
Figure 2. S. thermophilus 285 decreases expression of IL-1β, IL-2, and increases IL-6 by mouse spleen
cells. Spleen cells isolated from immunized mice (n = 3) were stimulated with S. thermophilus (ST)
ST285 and recall agonist MBP83–99 peptide for 24 h and secretion of (A) IL-1β, (B) IL-2, and (C) IL-6
were measured. Recall MBP83–99 peptide was used as the reference peptide, and media refers to spleen
cells from immunized mice (n = 3) without any additional recall peptide or ST285 probiotic bacteria
plus MBP83–99 peptide. Means are shown as plus or minus (±) standard error of the means. Symbols
represent the p value for the Tukey test (one way ANOVA) where * p < 0.05 and ** p < 0.01 and
*** p < 0.001.
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Figure 3. S. thermophilus 285 induces the anti-inflammatory cytokine profile by immunized mouse
splenocytes. Spleen cells isolated from immunized mice (n = 3) were stimulated with S. thermophilus
(ST) ST285 and the recall agonist MBP83–99 peptide for 24 h and the secretion of (A) IL-4, (B) IL-5, and
(C) IL-10 were measured. Recall MBP83–99 peptide, media alone, or recall MBP83–99 peptide plus ST285
are shown from immunized mice (n = 3). The means of readings for n = 3 mice were calculated and
presented as plus or minus (±) the standard error of the mean. Symbols represent the p value for the
Tukey test (one way ANOVA) where ** p < 0.01 and *** p < 0.001.
3.4. ST285 Does Not Alter the Secretion of Granulocyte-macrophage Colony-stimulating Factor by Mouse
Spleen Cells
Secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) did not show any change
by immunized mouse spleen cells upon co-culture with ST285 and agonist recall MBP83–99 peptide
compared to the negative control or MBP83–99 peptide (Figure 4), despite significant upregulation of
GM-CSF by ST285 on monocytes/macrophage cells [29].
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Figure 4. S. thermophilus 285 does not alter secretion of GM-CSF by mouse spleen cells. Spleen cells
isolated from immunized mice (n = 3) were stimulated with S. thermophilus (ST) ST285 and the recall
reference peptide for 24 hours and secretion of GM-CSF was measured. Recall MBP83–99 peptide, media
alone, or recall MBP83–99 peptide plus ST285 are shown from immunized mice (n = 3). The means
of readings for n = 3 mice were calculated and presented as plus or minus (±) the standard error of
the mean.
4. Discussion
The Th1 pro-inflammatory cytokines IFN-γ and TNF-α are both involved in the defense against
bacterial infections and in acute phase reactions. In MS, these two cytokines are implicated in the
pathogenesis of disease by stimulating CD4+ T cells against the myelin sheath. Mice immunized
with the mannan MBP83–99 peptide stimulated IFN-γ secretion, which was reduced in the presence of
ST285. This reduction is very important in the context of inflamed situations such as autoimmune
and inflammatory diseases, as any reduction in the amount of mediators that cause inflammation
is imperative in the relief of symptoms. We previously noted that high levels of TNF-α and IFN-γ
was secreted by the U937 monocytic cell line in the presence of ST285 [29]. However, the addition
of ST285 to the MBP83–99 recall peptide reduced IFN-γ secretion by mouse splenocytes. Spleen cells
were populated with B, T, NK cells, macrophages, and monocytes, while the U937 cell line that we
previously used were purely monocytic/macrophage cells. Additionally, the polarized inflammatory
state of cytokines as a result of the immunization regimen and further exposure of spleen cells to the
recall MBP83–99 peptide that operate as inflammatory stimuli, compared to the U937 monoclonal cells
only being exposed to ST285 bacteria, might give a clue as to the ability of ST285 probiotics to dampen
the inflammatory immune response in the instance of exposure to polyclonal spleen cells.
Secretion of IL-1β by monocytes is involved in regulating the immune and inflammatory responses
to infections and injuries; therefore, it has a role in innate immunity. IL-1β is also a major mediator in
inflammatory responses associated with various cellular activities such as differentiation, proliferation,
and apoptosis [39]. In addition, IL-1β is a regulator of inflammatory reactions and is involved in
the stimulation of the central nervous system through cyclooxygenase-2 (PTGS2/COX2), which is
involved in neurodegenerative disorders such as MS [33,40], Down’s Syndrome, Alzheimer’s disease,
and HIV-associated dementia [41,42].
We noted the secretion of IL-1β by immunized mouse spleen cells was marginally, but significantly
reduced in the presence of ST285 with the recall MBP83–99 peptide. We previously noted that ST285 did
not induce IL-1β cytokine to the U937 cell lines, however, significant upregulation of IL-1β mRNA was
induced by human PBMC [31] and monocytes post co-culture with ST285 [32]. It is therefore clear that
the immunized mouse spleens and the recall of T cells with the MBP83–99 peptide in the presence of
ST285 caused a reduction in IL-1β secretion. Likewise, IL-2 was marginally decreased in the presence
of ST285 compared to the increased secretion caused by the MBP83–99 peptide in the positive control.
Co-culturing human PBMC with ST285 also downregulates IL-2 mRNA expression [31].
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IL-6 is produced by activated immune cells including DC, B cells, and macrophages. Although IL-6
is associated with acute phase responses, it is also associated with a reduction of Th1 polarization, while
promoting Th2 differentiation, B cell maturation, and macrophage differentiation. Proliferation and
differentiation of Th2 cells changed the polarized Th1 environment and skewed the Th1/Th2 balance
toward Th2, which is beneficial in relieving autoimmune conditions such as MS. IL-6 production was
significantly higher (three times) in mouse splenocytes cultured with ST285 compared to the control,
hence, it is likely that ST285 bacteria may potentially change the balance toward a healthier state in MS.
We previously noted significant upregulation of IL-6 to human monocytes [manuscript submitted]
and to bulk PBMC co-cultures [31] with ST285, which are also in accord with the increase in IL-6
levels by the U937 promonocytic cell line co-cultured with ST285 [29]. Likewise, the commercially
used probiotic L. paracasei DG induces IL-6 cytokines to the THP-1 human monocyte cell line [43].
In contrast, ingestion of B. bifidum by mice did not increase the IL-6 levels, but boosted anti-oxidation
activities in the spleen and thymus of mice and improved other immune functions by changing the
gene expression of immune mediators [44].
It is likely that the constant-shifting in the equilibrium and the dynamics that exist between pro-
and anti-inflammatory cytokines will lead to some controversy in the research findings regarding IL-6.
On one hand, IL-6 may ease the autoimmune condition due to its downstream immunological effects.
On the other hand, elevated levels of pro-inflammatory effector T cell cytokines such as IFN-γ, IL-17 as
well as IL-6 are noted in patients with autoimmune myasthenia gravis and MS [45]. Thus, it might be
likely that the role that cytokines such as IL-6 play may depend on their bio-environment and may be
advantageous to the body, if probiotics such as ST285 are used for neutralization and/or reversing from
a pro- to an anti-inflammatory state in the body.
IL-4 is one of the important cytokines required for anti-inflammatory responses against
inflammatory conditions such as MS and allergies [29]. IL-4 production was significantly increased
by mouse spleen cells in the presence of the recall MBP83–99 peptide and ST285 compared to either
the MBP83–99 peptide alone or the negative control (media). Likewise, it was previously noted that
ST285 induced U937 monocytic cells to produce IL-4, although no changes to mRNA expression
levels of IL-4 were noted to human monocytes or to bulk human PBMC following co-cultures with
ST285 [31]. In contrast, feeding BALB/c mice with L. paracasei BEJ01 alone or combined with aflatoxins
B1 (AFB1) and fumonisin B1 (FB1) (known foodborne mycotoxins with immunomycotoxic effects on
human health) was used to evaluate L. paracasei BEJ01 detoxification [46]. Assessing different splenic
immunological factors indicated that exposure to these mycotoxins led to increased IL-4 mRNA levels,
oxidative stress, and immunotoxicity in the spleen [46] whereas the combined LAB treatment with
AFB1 or FB1 suppressed and normalized mRNA levels of IL-4, showing protective effects induced
by LAB against AFB1 and FB1 via diminishing toxin adhesion and bioavailability [46]. In contrast,
spleen cells isolated from BALB/c mice in vitro co-cultured individually with LAB strains (L. casei Lc2w
(Lc), L. plantarum CCFM47 (Lp), and L. acidophilus CCFM137 (La)) showed reduced IL-4 production
by spleen cells exposed to La only, while parallel animal studies displayed LAB-induced alleviation
of inflammation post airway allergy for all strains through increased Treg cells and modulation of
Th1/Th2 balance [47].
The anti-inflammatory cytokine IL-5 is produced by Th2 cells and mast cells. In the event of infection
with helminth parasites, IL-5 leads to a lesser risk of autoimmune disorders, which is indirectly accredited
to some therapeutic characteristics of IL-5 in autoimmune disorders. We noted a slight increase in the
IL-5 production by spleen cells in response to ST285, whereas no changes to the mRNA expression
levels of IL-5 were previously noted in ST285 co-cultures with human PBMC or human monocyte cells
[manuscripts submitted]. A study showed that treating mice with Fasciola hepatica excretion/secretions
(FHES) reduced EAE clinical signs due to a significant decrease in the infiltration of Th1 and Th17 cells
into the brain and an increase in IL-5 (and IL-23) response, with subsequent increase in eosinophils [48].
It is likely that the small but significant increase of IL-5 may be beneficial to MS.
Brain Sci. 2020, 10, 126 10 of 13
IL-10, an anti-inflammatory cytokine, is secreted by Th2 and Treg cells. Amongst all the
anti-inflammatory cytokines and chemokines, anti-inflammatory properties of IL-10 are the most
potent in suppressing inflammatory mediators by other activated immune cells (TNF-α, IFN-γ, IL-1,
IL-17, and IL-23 cytokines) [49]. A significant amplification in the IL-10 levels secreted by the spleen
cells in the presence of ST285 was noted, which was similarly shown for the U937 monocytic cell
line in the presence of ST285 and to human PBMC, although no significant changes were shown in
human monocyte cells [manuscripts submitted]. Likewise, oral administration of L. reuteri and L. lactis
strains to mice stimulated the production of anti-inflammatory IL-10 and Treg cells [50,51]. In addition,
sub-clinical studies of L. salivarius UCC118, L. lactis MG1363, and L. plantarum WCFS1 administered to
mice and re-exposure of their isolated bone marrow cells to the three bacterial co-cultures showed all
three strains differentially stimulated IL-10 production [52]. Correspondingly, when DC from spleen
and mesenteric lymph nodes of mice were matured using L. acidophilus X37 and exposed to commensal
gut Bifidobacterium longum Q46, L. acidophilus X37, and Escherichia coli Nissle 1917, increased IL-10 levels
were noted [53]. Similarly, after BALB/c mice were fed with L. paracasei BEJ01 alone or combined with
aflatoxins B1 and fumonisin B1, high IL-10 mRNA levels were induced [46]. In addition, mice fed with
kefir-derived Lactobacillus kefiri CIDCA 8348 also increased IL-10 gene expression [54]. In the context
of MS, the use of ST285 was shown to downregulate Th1 responses and upregulate Th2 responses,
something of the utmost importance to patients with MS to alleviate MS symptoms and/or reversal of
the disease [31].
5. Conclusions
Immunization of SJL/J mice with agonist MBP83–99 peptide conjugated to mannan induces Th1
pro-inflammatory IFN-γ responses and no Th2 anti-inflammatory responses when spleen cells are
co-cultured in vitro in the presence of the agonist recall MBP83–99 peptide. However, stimulation
of spleen cells with the recall MBP83–99 peptide in the presence of ST285 significantly increased the
secretion of IL-4, IL-6, and IL-10, along with mild upregulation in IL-2 and IL-5, suggesting a role for
ST285 in the activation of immune response phenotypes toward a predominant anti-inflammatory
profile, tolerance, and suppression of inflammation. In addition, ST285, downregulated the secretion
of IL-1a and IFN-γ—the immune mediators involved in Th1 type responses—collectively pointing to a
shift in immune responses from Th1 to a Th2 phenotype. More importantly, the significant increase of
IL-10 could further contribute by the differentiation of naïve CD4+ T cells and proliferation of Tregs,
which can also drive the immune balance further toward a dominant anti-inflammatory phenotype.
Additionally, given the drastic increase of GM-CSF in our previous studies of ST285 co-cultured with
the U937 monocytic cell line, human PBMC, and human monocyte cells, and no change to the secretion
of GM-CSF in spleen cells with GM-CSF being a major cytokine for proliferation and recruitment of
the immune cells, this might indicate a deliberate and purposeful neutralization of GM-CSF by ST285.
The effects of ST285 on the immune response could be used as a novel approach in modulating chronic
inflammatory and autoimmune conditions such as MS. Further studies should involve the effects
of ST285 in mice with EAE or be used to prevent EAE induction, which will pave the way for new
modalities for the treatment of MS in human clinical trials.
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